BRIEF-Eli Lilly & Hims & Hers Health Announce Agreement To Expand Access To Zepbound & Foundayo
Reuters2026/11/06 11:45Nov 6 (Reuters) - Eli Lilly and Company LLY.N:
ELI LILLY: CO, HIMS & HERS HEALTH ANNOUNCED AGREEMENT TO HELP EXPAND ACCESS TO ZEPBOUND (TIRZEPATIDE) & FOUNDAYO (ORFORGLIPRON)
ELI LILLY: AGREEMENT GIVES PATIENTS PATH TO FDA-APPROVED TREATMENTS AT SELF-PAY PRICE THROUGH THE HIMS & HERS PLATFORM
ELI LILLY: SELF-PAY PRICING STARTS AT $149 PER MONTH FOR FOUNDAYO & $299 PER MONTH FOR ZEPBOUND
ELI LILLY: HIMS & HERS HAS COMMITTED NOT TO OFFER ACCESS TO COMPOUNDED COPIES OF LILLY’S GLP-1S IN FUTURE
Further company coverage: LLY.N
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of Japan minutes turn hawkish: Most members believe a rate hike is needed soon, with a 70% probability of a hike in December
Minutes from the Bank of Japan show that several members believe a rate hike is needed in the near term, with a roughly 70% probability of an increase in December. Core inflation has met the target for the first time in 30 years, and the current policy rate stands at 1.25%.
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Crypto prices
More
